For over a year the future has lacked clarity. As parts of the world start to open up and the life sciences industry ramps back up to pre-pandemic activity, the fog of uncertainty is starting to lift. We are seeing an acceleration of digital transformation across the Life Sciences industry with the adoption of decentralized trials, real world evidence, and remote monitoring.

Good data governance can go a long way toward reducing business risk. If your content and your data are secure, you’ve eliminated danger to your customers’ information and secured your proprietary information. From a digital perspective, you’re ahead of the game. But data governance shouldn’t be your only concern.

Businesses sit on massive, ever-growing piles of data. According to Dave Reinsel, senior vice president, IDC's Global DataSphere, 64.2 zettabytes (ZB) of data was created or replicated in 2020. And the amount of digital data created over the next five years will be greater than twice the amount of data created since the advent of digital storage. But data isn’t just growing, it is spreading to more applications, more users, and more devices than ever.

90% of companies are on the cloud (Galov). That includes industries historically slow to adopt new technology, like Architecture, Engineering and Construction (AEC). However, recent economic and workplace disruptions have pushed AEC firms more aggressively into the public cloud waters - looking for cost effective ways to access compute power, more efficiently process data, provide access to files and applications, and tap into advanced analytics to draw insights from and manage data.

The sheer number of parties involved in a clinical trial results in increased complexity. The ability to tame this complexity is what separates high-growth biotechs from the rest. In order to keep up with the pace of innovation organizations must improve efficiencies while adhering to regulatory requirements, all in a drive to maintain consistent data quality.